We provide you with 20 years of free, institutional-grade data for HALO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HALO. Explore the full financial landscape of HALO stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-05 | 1159036 | HALO | 10-Q | Url |
| 2025-05-06 | 1159036 | HALO | 10-Q | Url |
| 2025-02-18 | 1159036 | HALO | 10-K | Url |
| 2024-10-31 | 1159036 | HALO | 10-Q | Url |
| 2024-08-06 | 1159036 | HALO | 10-Q | Url |
| 2024-05-07 | 1159036 | HALO | 10-Q | Url |
| 2024-02-20 | 1159036 | HALO | 10-K | Url |
| 2023-11-06 | 1159036 | HALO | 10-Q | Url |
| 2023-08-08 | 1159036 | HALO | 10-Q | Url |
| 2023-05-09 | 1159036 | HALO | 10-Q | Url |
| 2023-02-21 | 1159036 | HALO | 10-K | Url |
| 2022-11-08 | 1159036 | HALO | 10-Q | Url |
| 2022-08-09 | 1159036 | HALO | 10-Q | Url |
| 2022-05-10 | 1159036 | HALO | 10-Q | Url |
| 2022-02-22 | 1159036 | HALO | 10-K | Url |
| 2021-11-02 | 1159036 | HALO | 10-Q | Url |
| 2021-08-09 | 1159036 | HALO | 10-Q | Url |
| 2021-05-10 | 1159036 | HALO | 10-Q | Url |
| 2021-02-23 | 1159036 | HALO | 10-K | Url |
| 2020-11-02 | 1159036 | HALO | 10-Q | Url |
| 2020-08-10 | 1159036 | HALO | 10-Q | Url |
| 2020-05-11 | 1159036 | HALO | 10-Q | Url |
| 2020-02-24 | 1159036 | HALO | 10-K | Url |
| 2019-11-12 | 1159036 | HALO | 10-Q | Url |
| 2019-08-06 | 1159036 | HALO | 10-Q | Url |
| 2019-05-07 | 1159036 | HALO | 10-Q | Url |
| 2019-02-21 | 1159036 | HALO | 10-K | Url |
| 2018-11-06 | 1159036 | HALO | 10-Q | Url |
| 2018-08-07 | 1159036 | HALO | 10-Q | Url |
| 2018-05-10 | 1159036 | HALO | 10-Q | Url |
| 2018-02-20 | 1159036 | HALO | 10-K | Url |
| 2017-11-07 | 1159036 | HALO | 10-Q | Url |
| 2017-08-08 | 1159036 | HALO | 10-Q | Url |
| 2017-05-09 | 1159036 | HALO | 10-Q | Url |
| 2017-02-28 | 1159036 | HALO | 10-K | Url |
| 2016-11-07 | 1159036 | HALO | 10-Q | Url |
| 2016-08-09 | 1159036 | HALO | 10-Q | Url |
| 2016-05-09 | 1159036 | HALO | 10-Q | Url |
| 2016-02-29 | 1159036 | HALO | 10-K | Url |
| 2015-11-09 | 1159036 | HALO | 10-Q | Url |
| 2015-08-10 | 1159036 | HALO | 10-Q | Url |
| 2015-05-11 | 1159036 | HALO | 10-Q | Url |
| 2015-03-02 | 1159036 | HALO | 10-K | Url |
| 2014-11-10 | 1159036 | HALO | 10-Q | Url |
| 2014-08-11 | 1159036 | HALO | 10-Q | Url |
| 2014-05-12 | 1159036 | HALO | 10-Q | Url |
| 2014-02-28 | 1159036 | HALO | 10-K | Url |
| 2013-11-08 | 1159036 | HALO | 10-Q | Url |
| 2013-08-07 | 1159036 | HALO | 10-Q | Url |
| 2013-05-08 | 1159036 | HALO | 10-Q | Url |
| 2013-03-01 | 1159036 | HALO | 10-K | Url |
| 2012-11-08 | 1159036 | HALO | 10-Q | Url |
| 2012-08-09 | 1159036 | HALO | 10-Q | Url |
| 2012-05-07 | 1159036 | HALO | 10-Q | Url |
| 2012-03-12 | 1159036 | HALO | 10-K | Url |
| 2011-11-08 | 1159036 | HALO | 10-Q | Url |
| 2011-08-05 | 1159036 | HALO | 10-Q | Url |
| 2011-05-06 | 1159036 | HALO | 10-Q | Url |
| 2011-03-11 | 1159036 | HALO | 10-K | Url |
| 2010-11-05 | 1159036 | HALO | 10-Q | Url |
| 2010-08-06 | 1159036 | HALO | 10-Q | Url |
| 2010-05-07 | 1159036 | HALO | 10-Q | Url |
| 2010-03-12 | 1159036 | HALO | 10-K | Url |
| 2009-11-06 | 1159036 | HALO | 10-Q | Url |
| 2009-08-07 | 1159036 | HALO | 10-Q | Url |
| 2009-05-08 | 1159036 | HALO | 10-Q | Url |
| 2009-03-13 | 1159036 | HALO | 10-K | Url |
| 2008-11-07 | 1159036 | HALO | 10-Q | Url |
| 2008-08-08 | 1159036 | HALO | 10-Q | Url |
| 2008-05-09 | 1159036 | HALO | 10-Q | Url |
| 2008-03-14 | 1159036 | HALO | 10-K | Url |
| 2007-11-09 | 1159036 | HALO | 10-Q | Url |
| 2007-08-09 | 1159036 | HALO | 10-Q | Url |
| 2007-05-10 | 1159036 | HALO | 10-Q | Url |
| 2007-03-09 | 1159036 | HALO | 10-K | Url |
| 2006-11-09 | 1159036 | HALO | 10-Q | Url |
| 2006-08-08 | 1159036 | HALO | 10-Q | Url |
| 2006-05-10 | 1159036 | HALO | 10-Q | Url |
Halozyme Therapeutics, Inc(NASDAQ:HALO) 
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that ...
Website: http://www.halozyme.com
Founded: 1998
Full Time Employees: 132
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about HALO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.